{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
NCT00041756: Phase 2 Interventional Completed Osteoarthritis, Knee
(2002)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
PG-116800 is a member of the hydroxyproline-based hydroxamic acid class of matrix metalloproteinase (MMP) inhibitors. PG-116800 did not modify matrix structure in osteoarthritic patients. Also, it had unexpected side effects on muscle and skeleton; it limited joint mobility, and caused arthralgia, hand oedema, palmar fibrosis, Dupuytren’s contracture and persistent tendon thickness or nodules. PG-116800 failed to reduce left ventricular remodeling or improve clinical outcomes after myocardial infarction.
Status:
Investigational
Source:
NCT00511485: Phase 2 Interventional Completed Adenocarcinoma of the Lung
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Etarfolatide (EC20) is a conjugate of folic acid and peptidic metal-chelating moiety. Technetium Tc99m radiolabeled etarfolatide is a folate-targeted molecular imaging agent that is being developed to non-invasively identify tumors that express folate receptors and that may respond to folate-targeted therapy. It is being co-developed as the companion imaging agent to Vynfinit® (vintafolide) and EC1456 (folate-tubulysin).
Status:
Investigational
Source:
NCT01345357: Phase 1 Interventional Completed Solid Tumors or Mantle Cell Lymphoma
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03846219: Phase 2 Interventional Active, not recruiting Relapsing-Remitting Multiple Sclerosis (RRMS)
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Vidofludimus (SC12267; 4SC-101) is a novel oral immunomodulator inhibiting dihydroorotate dehydrogenase (DHODH) and the expression of proinflammatory cytokines including interleukin-17 (IL17A and IL17F) and interferon-gamma. This drug is in the clinical trial for the treatment of inflammatory bowel diseases and Rheumatoid arthritis.
Status:
Investigational
Source:
NCT00412620: Phase 2 Interventional Terminated Schizophrenia
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Abbott Laboratories was developing the selective dopamine D3 receptor antagonist, ABT-925 (formerly A 437203), for the treatment of schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT 925 was undergoing phase II clinical development for the treatment of schizophrenia. However, development was discontinued in December 2007.
Status:
Investigational
Source:
NCT00551850: Phase 1 Interventional Completed Advanced Cancer
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
MP-412 (AV-412) is a potent dual inhibitor of EGFR and ErbB2 tyrosine kinases, including the mutant EGFR (L858R,T790M), which is clinically resistant to the EGFR-specific kinase inhibitors erlotinib and gefitinib. AV-412 has potential as a therapeutic agent for the treatment of cancers expressing EGFR and ErbB2, especially those resistant to the first generation of small-molecule inhibitors.AVEO Pharmaceuticals was developing AV-412 for the treatment of cancer, however development has been discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Tandamine was developed as a selective serotonin reuptake inhibitor for the treatment of depression. Tandamine participated in clinical trials in hospitalized depressed patients, where it showed that the well-tolerated drug could be of some benefit for retarded depressions. In addition, was found in human volunteers, that tandamine possessed significant anticholinergic activity, to reduce appetite and to produce sedation. However, this drug has never been marketed.
Status:
Investigational
Source:
NCT01551147: Phase 2 Interventional Completed Asthma
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Gemilukast (ONO-6950) is an orally active compound that has been evaluated for the treatment of asthma. It is an CysLT1 and CysLT2 antagonist. Activation of CysLT2 receptors has been suggested to contribute to antigen-induced bronchoconstriction (constriction of the airways in the lungs) in certain asthma patients. In addition to its CysLT1 and CysLT2 antagonist activity, Gemilukast was shown to dose-dependently reduce LTC4-induced bronchoconstriction in asthmatic models, and reduce antigen-induced constriction of isolated human bronchi. A phase II trial with Gemilukast was discontinued in 2018.
Status:
Investigational
Source:
NCT01457677: Phase 2 Interventional Completed Major Depressive Disorder
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Decoglurant is a negative allosteric modulator of the mGlu2 and mGlu receptors developed by Roche. Decoglurant was investigated in a phase 2 clinical trials in patients with major depressive disorder. Negative results were reported and the development was discontinued in 2015.
Status:
Investigational
Source:
Redox Rep. 2011;16(3):91-100.: Phase 2 Veterinary clinical trial Completed Mouth Neoplasms/chemically induced/pathology/prevention & control
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
